Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares (ARCA: EVAV)

Latest news for Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares (ARCA:EVAV)

Consumer Cyclical

Industrials

Technology

Other

Direxion is a financial services firm known for its range of leveraged and inverse ETFs. These ETFs provide exposure to various market sectors, including technology, real estate, and commodities. Direxion's ETFs are designed for traders and investors looking to capitalize on market trends, volatility spikes, and news events.

Direxion

The Index is designed to track the performance of electric and autonomous vehicles companies. Indxx (the Index Provider) defines electric and autonomous vehicles companies as those companies that derive at least 50% of their revenues from Manufacturers companies that manufacture and sell electric or autonomous vehicles, Enablers companies that build infrastructure or create technology for electric or autonomous vehicles, such as charging docks and batteries, Software and Technology Services companies that engage in the development of software and technology for electric or autonomous vehicles.

Gs Financial Square Treasury Instruments Fund

Nio Inc. ADR

Tesla, Inc.

Xpeng Inc.

Li Auto, Inc.

Rivian Automotive

Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares

News

Federal Reserve

Markets

Tech

Trading Ideas

ETFs

ETF Opportunities Trust T-Rex 2X Long Apple Daily Target ETF

AAPX

Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares

EVAV

LABU

AdvisorShares Trust AdvisorShares MSOS 2x Daily ETF

MSOX

YINN

Wall Street was upbeat last week with the S&amp;P 500 adding 0.6%, the Dow Jones gaining 1.1% and the Nasdaq advancing 1.4%. The benchmark U.S. treasury yield started the week at 4.63%, hit a high of 4.69% and ended the week at 4.50%. 

Best Leveraged ETFs of Last Week

ChargePoint

Analyst Color

Equities

Downgrades

Price Target

Analyst Ratings

Movers

CHPT

SIMS

TSLA

Goldman Sachs analyst downgrades CHPT to Sell, citing slower EV sales and increasing competition. Delaney lowers price target to $1.50.

Shock For ChargePoint - Analyst Downgrades Amid Sluggish EV Market And Rising Competition

Earnings

Earnings Beats

Cullen/Frost Bankers Q2 2024 GAAP EPS $2.21 Beats $2.07 Estimate, Sales $528.811M Beat $515.357M Estimate

AGCO Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, announced it has entered into a definitive agreement to sell the majority of its Grain &amp; Protein business to American Industrial Partners ("AIP") in an all-cash transaction valued at $700 million, subject to working capital and other customary closing adjustments.

Asset Sales

AGCO

AGCO Announces Definitive Agreement To Sell Its Grain & Protein Business In An All-Cash Transaction Valued At $700M

LiqTech International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>), a high-tech filtration company that manufactures and markets highly specialized filtration products and systems for marine, and Danbee Marine,&nbsp;a South Korean-based maritime representative to the shipping industry, entered into a partnership agreement with Danbee to market LiqTech's marine scrubber water treatment solutions within South Korea, the second largest ship building market in the world after China.

Global

LIQT

LiqTech And Danbee Marine Co. Ltd. Enter Agreement For Marine Scrubber Water Treatment Solutions For The South Korean Market

EW: -24% &#x7C; <a href="https://www.benzinga.com//node/39952400">Edwards Lifesciences shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. Also, the company acquired JenaValve and Endotronix.</a>
&nbsp;
MXL: -27% &#x7C; <a href="https://www.benzinga.com//node/39952857">MaxLinear shares are trading lower after the company reported worse-than-expected Q2 financial results.</a>
&nbsp;
&nbsp;POAI: 117% &#x7C; <a href="https://www.benzinga.com//node/39953717">Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results</a>

POAI

Market-Moving News for July 25th

GLYC

GlycoMimetics To Conduct Additional Clinical Trial For Uproleselan In R/R Acute Myeloid Leukemia After FDA Meeting; Initiates Strategic Review And Corporate Restructuring, Reducing Workforce By 80%; Engages Lucid Capital Markets As Strategic Advisor; Advancing Phase 2/3 Study Of Uproleselan In Newly Diagnosed AML Patients With NCI And Alliance For Clinical Trials; Cash Expected To Fund Company Into Q2 2025

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and lowers the price target from $85 to $77.

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Lowers Price Target to $77

Agreement provides Ohio community banks a commercial and industrial loan-acquisition and risk-management program
Voya Investment Management, the asset management business of Voya Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>), and OBL BankServices, Inc. (OBLBS), a subsidiary of the Ohio Bankers League, announced today they have entered into a commercial and industrial (C&amp;I) loan growth partnership program known as the Voya Senior Loan Bank Advisory Program.
While community and small regional banks have historically excelled at small business underwriting and relationship management, Voya's C&amp;I program recognizes the syndicated loan market demands a broader industry knowledge and timely action. Participating commercial banks benefit from Voya's unique market leadership, experience, relationships, credit risk management, training and sourcing capabilities while effectively keeping independent research and decision-making within their walls, thus satisfying regulatory requirements.

VOYA

Voya Investment Management And OBL BankServices Enter Into A Commercial And Industrial Loan Growth Partnership Program Known As The Voya Senior Loan Bank Advisory Program.

In the preceding three months, 4 analysts have released ratings for Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $227.5, a high estimate of $240.00, and a low estimate of $200.00. This current average has increased by 9.64% from the previous average price target of $207.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1721912479_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Jones Lang LaSalle among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$240.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jones Lang LaSalle. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jones Lang LaSalle compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Jones Lang LaSalle's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Jones Lang LaSalle's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JLL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jones Lang LaSalle analyst ratings.</a>
<h2>Discovering Jones Lang LaSalle: A Closer Look</h2>
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
<h3>Breaking Down Jones Lang LaSalle's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Jones Lang LaSalle's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.67% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.29%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Jones Lang LaSalle's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.05%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Jones Lang LaSalle's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.42% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Jones Lang LaSalle's debt-to-equity ratio is below the industry average. With a ratio of 0.56, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Jones Lang LaSalle: What You Need To Know

8 analysts have shared their evaluations of AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $22.0, a high estimate of $26.00, and a low estimate of $18.00. This current average has increased by 3.0% from the previous average price target of $21.36. 
<img src="https://www.benzinga.com/files/images/story/2024/1721912469_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AT&amp;T. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$23.00</td>
<td>$22.50</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Bryan Kraft</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Timothy Horan</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>John Hodulik</td>
<td>UBS</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AT&amp;T. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AT&amp;T compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for AT&amp;T's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of AT&amp;T's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/T/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AT&amp;T analyst ratings.</a>
<h2>About AT&amp;T</h2>
The wireless business contributes about two thirds of AT&amp;T's revenue. The firm is the third-largest US wireless carrier, connecting 72 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 16% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential fixed-line services, about 11% of revenue, primarily consist of broadband internet access, serving 14 million customers. AT&amp;T also has a sizable presence in Mexico, with 22 million customers, but this business only accounts for 3% of revenue. The firm still holds a 70% equity stake in satellite television provider DirecTV but does not consolidate this business in its financial statements.
<h3>Understanding the Numbers: AT&amp;T's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: AT&amp;T's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -0.37%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: AT&amp;T's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AT&amp;T's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.27%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): AT&amp;T's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.84%, the company may face hurdles in achieving optimal financial performance.
Debt Management: AT&amp;T's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.44, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Assess AT&T: What You Need To Know

Allegion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $117.5, with a high estimate of $125.00 and a low estimate of $112.00. Experiencing a 4.28% decline, the current average is now lower than the previous average price target of $122.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1721912456_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Allegion among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$117.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$112.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$125.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$116.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Allegion. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Allegion compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Allegion's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Allegion's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALLE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Allegion analyst ratings.</a>
<h2>All You Need to Know About Allegion</h2>
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2023, Allegion generated 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy and Switzerland-based Dormakaba.
<h3>Key Indicators: Allegion's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Allegion faced challenges, resulting in a decline of approximately -3.15% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Allegion's net margin excels beyond industry benchmarks, reaching 13.85%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Allegion's ROE excels beyond industry benchmarks, reaching 9.28%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Allegion's ROA excels beyond industry benchmarks, reaching 2.88%. This signifies efficient management of assets and strong financial health.
Debt Management: Allegion's debt-to-equity ratio stands notably higher than the industry average, reaching 1.49. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLE

Expert Outlook: Allegion Through The Eyes Of 4 Analysts

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to B<a href="https://pro.benzinga.com/">enzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Conn&#8217;s Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CONN#NASDAQ">CONN</a>)</h3>
<ul>
<li>On June 26, Conn's received a delinquency notification letter from the Nasdaq. The company's stock fell around 48% over the past five days and has a <a href="https://www.benzinga.com/quote/CONN">52-week low of $0.31</a>.</li>
<li>RSI Value: 17.61</li>
<li>CONN Price Action: Shares of Conn&#8217;s closed at $0.35 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072524&amp;t=be2bearmibe3na1">latest CONN news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="689" height="729" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25085821/Screenshot-2024-07-25-at-6.28.15-PM.png" alt="" class="wp-image-456773" style="width:422px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25085821/Screenshot-2024-07-25-at-6.28.15-PM.png 689w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25085821/Screenshot-2024-07-25-at-6.28.15-PM-284x300.png 284w" sizes="(max-width: 689px) 100vw, 689px" /></a></figure>
<h3 class="wp-block-heading">Levi Strauss &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>)&nbsp;</h3>
<ul>
<li>On June 26, Levi Strauss reported quarterly earnings of 16 cents per share which beat the analyst consensus estimate of 11 cents. "We delivered another strong quarter driven by the Levi's brand's prominence at the center of culture, a robust pipeline of newness and innovation, and continued momentum in our global direct-to-consumer channel. Our amplified focus on women's and denim lifestyle is delivering outsized growth and driving meaningful market share gains," said Michelle Gass, CEO of Levi Strauss &amp; Co. The company's stock fell around 24% over the past month. It <a href="https://www.benzinga.com/quote/LEVI">has a 52-week low</a> of $12.42.</li>
<li>RSI Value: 25.55</li>
<li>LEVI Price Action: Shares of Levi Strauss fell slightly to close at $17.50 on Wednesday.</li>
<li>Benzinga Pro's charting tool helped identify the <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072524&amp;t=be2bearmibe3na1">trend in LEVI stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="688" height="755" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25085929/Screenshot-2024-07-25-at-6.29.22-PM.png" alt="" class="wp-image-456777" style="width:432px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25085929/Screenshot-2024-07-25-at-6.29.22-PM.png 688w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25085929/Screenshot-2024-07-25-at-6.29.22-PM-273x300.png 273w" sizes="(max-width: 688px) 100vw, 688px" /></a></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39950906/nasdaq-s-p-500-record-worst-session-since-2022-amid-tesla-alphabet-selloff-investor-optimism-decrea">Nasdaq, S&amp;P 500 Record Worst Session Since 2022 Amid Tesla, Alphabet Selloff: Investor Optimism Decreases Further</a></li>
</ul>

Long Ideas

CONN

LEVI

Top 2 Consumer Stocks Which Could Rescue Your Portfolio In Q3

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Jumia Technologies AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NYSE">JMIA</a>) is not making a <a href="https://www.benzinga.com/quote/JMIA/earnings">lot of money.</a>
The company will release results for the second quarter before the opening bell on Tuesday, Aug. 6.
Benchmark analyst Fawne Jiang initiated coverage of Jumia&#8217;s stock on July 9 with a Buy rating and a $14 price target. The African e-commerce company is poised to benefit from multi-year and potentially multi-decade e-commerce growth in the region.
See Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/23/03/31299793/exclusive-jim-cramer-recommended-svb-financial-in-february-an-example-of-his-reverse-midas-to">Jim Cramer Recommended This Bank A Month Before It Collapsed, An Example Of &#8216;His Reverse Midas Touch&#8217;</a>
When asked about Adeia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>), he said, &#8220;I would actually put Trade, TTD, which was down very badly today off of Alphabet, and I think that's the one you want to buy.&#8221;
Adeia will announce its financial results for the second quarter on Tuesday, Aug. 6, after the closing bell. Analysts expect the company to report quarterly earnings at 23 cents per share on revenue of $84.25 million.
The &#8220;Mad Money&#8221; host said he likes Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>). &#8220;I think it's absolutely terrific. It's going to get hammered along with the rest of the rotation,&#8221; he added.
On July 17, Cantor Fitzgerald analyst C J Muse maintained Broadcom with an Overweight rating, while adjusting target to $200 from $2,000 (10-1 stock split).
&#8220;I've always been a believer in the gold stocks,&#8221; Cramer said when asked about Hecla Mining Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HL#NYSE">HL</a>). &#8220;It's not always worked out, but right now it is. Yours is good.&#8221;
Hecla Mining will release its second quarter operational and financial results after the closing bell on Aug. 6. Analysts expect the company to report quarterly earnings at 4 cents per share on revenue of $219.2 million.
Cramer recommended buying AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>). &#8220;All I know is that drones work,&#8221; he noted.
On July 23, René Carbone Bardorf joined AeroVironment (AV) as Vice President of Marketing and Communications.
Price Action:
<ul>
<li>Adeia shares fell 3.6% to settle at $11.38 on Wednesday.</li>
<li>Hecla Mining shares fell 1% to settle at $5.88.</li>
<li>Jumia dipped 11.3% to close at $12.24 during Wednesday's session.</li>
<li>AeroVironment shares slipped 0.7% to settle at $170.31.</li>
<li>Broadcom shares fell 7.6% to settle at $151.34 on Wednesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39931967/nvidia-mcdonalds-and-2-other-stocks-insiders-are-selling">Nvidia, McDonald&#8217;s And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Media

ADEA

AVAV

AVGO

JMIA

Jim Cramer: This Tech Stock Is 'Absolutely Terrific,' But Jumia? It's Not Making A Lot Of Money

Analysts' ratings for NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) over the last quarter vary from bullish to bearish, as provided by 16 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $273.94, with a high estimate of $346.00 and a low estimate of $213.00. A 8.54% drop is evident in the current average compared to the previous average price target of $299.53. 
<img src="https://www.benzinga.com/files/images/story/2024/1721912445_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive NICE. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tavy Rosner</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$286.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$213.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Michael Latimore</td>
<td>Northland Capital Markets</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$346.00</td>
<td>$339.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$225.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$300.00</td>
<td>$343.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$280.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$270.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$343.00</td>
<td>$343.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NICE. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of NICE compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into NICE's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NICE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NICE analyst ratings.</a>
<h2>Discovering NICE: A Closer Look</h2>
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. The company provides data analytics-based solutions through both a cloud platform and on-premises infrastructure. Within customer engagement, Nice's CXone platform delivers solutions focused on contact center software and workforce engagement management, or WEM. Contact center offerings include solutions for digital self-service, customer journey and experience optimization, and compliance. WEM products optimize call center efficiency, leveraging data and AI analytics for call volume forecasting and agent scheduling. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money laundering, and compliance solutions.
<h3>Key Indicators: NICE's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining NICE's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.29% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: NICE's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.13%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): NICE's ROE excels beyond industry benchmarks, reaching 3.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): NICE's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.09% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.17, NICE adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NICE

Peeling Back The Layers: Exploring NICE Through Analyst Insights

CTRM

Castor Maritime Announces Agreement To Acquire 2015-Built Ultramax Dry Bulk Carrier For $25.5M Through Wholly-Owned Subsidiary

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $83 to $88.

Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $88

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.78, a high estimate of $400.00, and a low estimate of $240.00. Observing a 13.18% increase, the current average has risen from the previous average price target of $297.56. 
<img src="https://www.benzinga.com/files/images/story/2024/1721912420_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of United Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Thome</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$321.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$375.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of United Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of United Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>About United Therapeutics</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>United Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: United Therapeutics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 33.7%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 45.24%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): United Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.42% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.49% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: United Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UTHR

Navigating 9 Analyst Ratings For United Therapeutics

Wedbush analyst David Chiaverini maintains Pacific Premier Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBI#NASDAQ">PPBI</a>) with a Neutral and raises the price target from $23 to $25.

PPBI

Wedbush Maintains Neutral on Pacific Premier Bancorp, Raises Price Target to $25

In his speech at the Republican National Convention on Wednesday, Vice Presidential nominee J.D. Vance explained America&#8217;s housing affordability crisis and contrasted it with <a href="https://www.benzinga.com/real-estate/24/07/39634709/housing-market-stuck-until-2026-economists-reveal-surprising-reasons">what economists and policy experts say</a>.
The Ohio senator and former venture capitalist Vance offered a vision of a housing market battered by Wall Street malfeasance, stagnant wages, and illegal immigration. &#8220;Wall Street barons crashed the economy and American builders went out of business,&#8221; Vance said during his speech. &#8220;As tradesmen scrambled for jobs, houses stopped being built.&#8221;
Don't Miss:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>
&#8220;And then the Democrats flooded this country with millions of illegal aliens,&#8221; he continued. &#8220;So citizens had to compete with people who shouldn&#8217;t even be here for precious housing.&#8221;
In June, he tweeted, &#8220;Not having 20 million illegal aliens who need to be housed (often at public expense) will make housing more affordable for American citizens.&#8221; That is not the problem, the data suggests. According to the National Review, roughly 223 million Americans own or live in homes that are owned, compared to about three million illegal immigrants who are thought to reside in owner-occupied homes. More than that, mass deportation, as suggested by Vance, could even exacerbate the housing affordability problem. Immigrants make up a sizable portion of the construction workforce, and their removal could further slow housing production. According to a report issued in 2021 by the National Association of Home Builders, immigrants account for about 24% of workers in the construction industry.
See Also: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
Economists and housing experts argue that the problem goes back to the 2008 financial crash, which led to a drop in new home construction. Then, restrictive zoning laws, the COVID-19 pandemic, increased construction costs, and changing demographics drove up housing prices. According to the Government Accountability Office, the current shortage of affordable housing in the U.S. is the product of high interest rates, low inventory, and the growing number of adults looking for homes. More than that, during the pandemic, record-low interest rates and a shift toward remote work fueled demand, particularly for larger homes. The combination of limited supply and increased demand drove prices to historic highs in many markets.&nbsp;
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
&#8220;The simple fact is there are not enough homes in this country, and that&#8217;s pushing homeownership out of reach for too many families,&#8221; Orphe Divounguy, senior economist at Zillow, said in June. &#8220;Filling the housing shortage is the long-term answer to making housing more affordable. We are in a big hole, and it will take more than the status quo to dig ourselves out of it." According to Zillow, despite recent efforts to ramp up construction, the housing shortage is worsening. The deficit <a href="https://www.benzinga.com/real-estate/24/06/39417022/zillow-economist-admits-we-are-in-a-big-hole-as-u-s-housing-shortage-hits-4-5-million-despite-constr">grew to 4.5 million homes in 2022</a>, up from 4.3 million the previous year.
While the pandemic sparked a surge in homebuilding, with 2022 marking the strongest year for construction since the early days of the Great Recession, the uptick in building activity has been insufficient to meet the growing demand. While 1.4 million new homes were built in 2022, U.S. households increased by 1.8 million during the same period.&nbsp;
As demand continues to outpace supply, prices remain elevated, putting homeownership increasingly out of reach for many Americans – which is not what Vance suggested during his speech. 
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>Can you guess which type of investments Morgan Stanley says will reach $2.7 trillion by 2027?<a href="https://www.benzinga.com/money/percent"> It even offers up to 20% APY potential to accredited investors up to $300 back in bonus for new users.</a></li>
</ul>

Real Estate

Here's What Republican VP Nominee JD Vance Has Said About The Housing Market – You Might Be Shocked

INDOCHINO, the global leader in custom apparel, and Nordstrom, the renowned fashion retailer, are pleased to announce the expansion of their successful partnership with the addition of five new INDOCHINO shop-in-shop locations across the United States.
Building upon the phenomenal success of this collaboration since 2020, INDOCHINO will now offer its made to measure suiting experience in the following Nordstrom locations:
<ul>
<li>Nordstrom Los Cerritos Center - Cerritos, CA</li>
<li>Nordstrom Alderwood Mall - Lynnwood, WA</li>
<li>Nordstrom Thousand Oaks - Thousand Oaks, CA</li>
<li>Nordstrom Irvine Spectrum Center - Irvine, CA</li>
<li>Nordstrom Fashion Centre at Pentagon City - Pentagon City, VA</li>
</ul>

Nordstrom Strengthens Partnership With INDOCHINO, With The Addition Of 5 New Shop-In-Shop Locations Across The US

4 analysts have shared their evaluations of Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.0, a high estimate of $40.00, and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 11.11% from the previous average price target of $31.50.
<img src="https://www.benzinga.com/files/images/story/2024/1721912409_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Flex. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$39.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Hold</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Flex. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Flex compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Flex's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Flex's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FLEX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Flex analyst ratings.</a>
<h2>Delving into Flex's Background</h2>
Flex Ltd is a contract manufacturing company providing comprehensive electronics design, manufacturing, and product management services to electronics and technology companies. The company's operating segments include Flex Agility Solutions (FAS) and Flex Reliability Solutions (FRS). Flex Agility Solutions segment includes markets such as Communications, Enterprise and Cloud; Lifestyle; and Consumer Devices. Flex Reliability Solutions segment includes markets such as Automotive, Health Solutions, and Industrial.
<h3>Unraveling the Financial Story of Flex</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Challenges: Flex's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -20.02%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Flex's net margin is impressive, surpassing industry averages. With a net margin of 8.77%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Flex's ROA stands out, surpassing industry averages. With an impressive ROA of 2.05%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Flex's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.7, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FLEX

The Latest Analyst Ratings For Flex

Canada EV push: Zero-emission car mandate expected this week

Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares declares quarterly distribution of $0.3356

URNM, WGMI and URNJ among weekly ETF movers

YINN, KOLD and YANG among weekly ETF movers

Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares declares quarterly distribution of $0.1252

FAZ, NAIL and KRBN among weekly ETF movers

LABU, YANG and LABD among weekly ETF movers

JNUG, AGQ and CONY among weekly ETF movers

Direxion Daily Electric and Autonomous Vehicles Bull 2X Shar declares quarterly distribution of $0.1343

AAPB

AAPU

BDRY

BNKD

CONL

CONY

DRIV

EVXX

FDRV

GDXD

GDXU

JNUG

KARS

KEUA

KOLD

KORU

KRBN

LABD

NAIL

NVDL

NVDQ

NVDU

NVDX

STLA

TSDD

TSLR

TSLZ

URNJ

URNM

WEED

WGMI

YANG

Wall Street was upbeat last week with the S&amp;P 500 adding 0.6%, the Dow Jones gaining 1.1% and the Nasdaq advancing 1.4%. The benchmark U.S. treasury yield started the week at 4.63%, hit a high of 4.69% and ended the week at 4.50%.&nbsp;

The Fed&#39;s plan to slower the balance sheet tightening process and the release of downbeat jobs data (which triggered bets over sooner-than-expected rate cuts) dragged down bond yields last week. The U.S. economy added 175,000 jobs in April, well below Wall Street expectations of 240,000. Health care and social assistance led the way with a gain of 87,000 jobs.

Meanwhile, corporate earnings have been bullish with Apple and Amazon coming up with both line beats. The corporate commentaries released throughout the week indicated the importance of AI growth and investments.

Meanwhile, crude oil ETF United States Oil Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) dropped about 6.2% last week on weak demand growth and less supply worries emanated from the Gaza-Israel peace talk. Higher U.S. crude output too played its role in driving down the price of oil.

Against this backdrop, below we highlight winning leveraged ETFs of last week.

<h3>ETF Areas in Focus</h3>

Direxion Daily S&amp;P Biotech Bull 3x Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LABU#NYSE">LABU</a>) &ndash; Up 24.55%

The U.S. benchmark treasury yield fell sharply last week. This boosted growth stocks and biotech technology. Novel drug launches, likely low rates and potential easy access to funds should buoy the zone in the near term.

Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVAV#NYSE">EVAV</a>) &ndash; Up 22.9%

Several electric vehicle stocks have been in sweet spot lately, as EV giant Tesla has surged post earnings. Chinese EV companies Nio and Xpeng have seen strong sales growth in 2024 despite massive price war. Nio stock was up 19% last week. Further, several auto companies are signing deals with Chinese tech companies to facilitate their innovations on AI and &quot;smart cars.&quot;

T-Rex 2X Long Apple Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/AAPX#BATS">AAPX</a>) &ndash; Up 16.8%

Apple stock gained 5.8% last week on upbeat earnings. Apple reported robust second-quarter fiscal 2024 results, wherein it beat estimates on both earnings and revenues. The iPhone manufacturer lifted its dividend payments and unveiled a record share buyback program despite the steep decline in iPhone sales.

Apple, which lags behind its peer in adopting AI, is gearing up for significant events that are expected to shape its future trajectory. A media event scheduled for May 7 is anticipated to unveil new iPad models and the annual Worldwide Developers Conference (WWDC), starting Jun 10, is anticipated to provide AI-related announcements and insights into the company&#39;s AI strategy.

Direxion Daily FTSE China Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YINN#NYSE">YINN</a>) &ndash; Up 16.5%

Despite the Chinese economy&#39;s poor performance last year, global investors are returning to its equities this year. Compelling valuation, market restructuring, billions in buybacks, the AI boom and its impact on various industries have been boosting the space, of late. Foreign carmakers are joining hands with Chinese companies operating in artificial intelligence and other smart car technology. China tech ETF CQQQ added 6.4% last week while Alibaba and Baidu gaining about 7% and 8%, respectively.

AdvisorShares MSOS 2x Daily ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOX#NYSE">MSOX</a>) &ndash; Up 14.1%

Shares of cannabis companies surged last week after the U.S. Department of Justice (DoJ) moved to reclassify marijuana as a less dangerous schedule III drug. This indicates a moderate to low risk of physical and psychological dependence. Cannabis firms would stand to gain significantly as they would no longer fall under the purview of Section 280E of the U.S. federal tax code, presenting one of the most notable advantages.

<a href="https://www.zacks.com/stock/news/2268454/best-leveraged-etfs-of-last-week?cid=CS-BENZ-FT-etf_news_and_commentary-2268454">To read this article on Zacks.com click here.</a>

ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) shares are trading lower after Goldman Sachs analyst Mark Delaney downgraded the stock to Sell (from Neutral) and cut the <a href="https://www.benzinga.com/quote/CHPT/analyst-ratings" target="_blank" rel="noreferrer noopener">price target to $1.50 (from $2.00)</a>.



The analyst&#8217;s bearish stance is due to expected&nbsp;slower growth in the number of EVs on the road in the U.S. and rising competition in EV charging.



In particular, Delaney expects the company to be impacted by slower U.S. EV sales as about 80% of its revenue is derived from North America.



Also, the analyst sees ChargePoint to face major competition, as Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) recently sold its chargers as a merchant business in select situations, along with ChargePoint&#8217;s general shift to multi-sourcing in North America.



Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37519013/chargepoints-shifting-fortunes-analyst-lowers-forecast-citing-slow-ev-market-and-em" rel="noreferrer noopener">ChargePoint&#8217;s Shifting Fortunes: Analyst Lowers Forecast Citing Slow EV Market And Emerging Cost Reduction Strategies</a>



The analyst says ChargePoint is now partnering with AcBel, which it expects to meaningfully reduce its costs as it ramps up this relationship and works off inventory of existing products.



Delaney expects U.S. EV sales growth to slow down considerably versus prior quarters in the first quarter of FY24, based on current market conditions and the finalized EPA emissions standards for 2027-2032.



However, if demand for its chargers is stronger than anticipated, the analyst looks to be more positive on the stock.



Consequently, the analyst lowered EPS (incl. SBC) estimates to $(0.65) from $(0.60) for FY25, $(0.50) from $(0.35) for FY26, and $(0.35) from $(0.05) for FY27 on lower revenue and margins.&nbsp;



Investors can gain exposure to the stock via&nbsp;Direxion Shares ETF Trust Direxion Daily Electric And Autonomous Vehicles Bull 2X Shares&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVAV#NYSE">EVAV</a>) and&nbsp;SPDR S&amp;P Kensho Intelligent Structures ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIMS#NYSE">SIMS</a>).



Price Action: CHPT shares are down 3.78% at $1.78 on the last check Tuesday.



Photo via Wikimedia Commons

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares

News

Latest news for Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares (ARCA:EVAV)

Monday, May 06, 2024

Tuesday, April 09, 2024